43,188 Shares in HilleVax, Inc. (NASDAQ:HLVX) Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new position in shares of HilleVax, Inc. (NASDAQ:HLVX) in the fourth quarter, Holdings Channel reports. The fund bought 43,188 shares of the company’s stock, valued at approximately $89,000.

Other large investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in HilleVax during the fourth quarter worth approximately $26,000. SG Americas Securities LLC boosted its stake in HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock worth $38,000 after purchasing an additional 6,916 shares during the period. Ieq Capital LLC boosted its stake in HilleVax by 71.1% in the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock worth $47,000 after purchasing an additional 9,344 shares during the period. Barclays PLC boosted its stake in HilleVax by 255.6% in the 3rd quarter. Barclays PLC now owns 42,033 shares of the company’s stock worth $74,000 after purchasing an additional 30,213 shares during the period. Finally, Jane Street Group LLC boosted its stake in HilleVax by 81.7% in the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after purchasing an additional 35,546 shares during the period. 86.42% of the stock is currently owned by institutional investors.

HilleVax Stock Up 5.5 %

HLVX stock opened at $1.54 on Thursday. HilleVax, Inc. has a 12-month low of $1.34 and a 12-month high of $16.31. The company has a market cap of $77.22 million, a price-to-earnings ratio of -0.50 and a beta of 0.86. The company has a 50 day moving average of $1.72 and a two-hundred day moving average of $1.84.

HilleVax (NASDAQ:HLVX) last released its earnings results on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). On average, research analysts anticipate that HilleVax, Inc. will post -2.64 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of HilleVax in a research note on Monday, March 31st. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat, HilleVax currently has a consensus rating of “Hold” and an average price target of $3.00.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.